Drug conjugation to hyaluronan widens therapeutic indications for ovarian cancer.

Abstract

Management of ovarian cancer still requires improvements in therapeutic options. A drug delivery strategy was tested that allows specific targeting of tumor cells in combination with a controlled release of a cytotoxic molecule. To this aim, the efficacy of a loco-regional intraperitoneal treatment with a bioconjugate (ONCOFID-S) derived by chemical linking of SN-38, the active metabolite of irinotecan (CPT-11), to hyaluronan was assessed in a mouse model of ovarian carcinomatosis. In vitro, the bioconjugate selectively interacted with ovarian cancer cells through the CD44 receptor, disclosed a dose-dependent tumor growth inhibition efficacy comparable to that of free SN-38 drug, and inhibited Topoisomerase I function leading to apoptosis by a mechanism involving caspase-3 and -7 activation and PARP cleavage. In vivo, the intraperitoneal administration of ONCOFID-S in tumor-bearing mice did not induce inflammation, and evidenced an improved therapeutic efficacy compared with CPT-11. In conclusion, SN-38 conjugation to hyaluronan significantly improved the profile of in vivo tolerability and widened the field of application of irinotecan. Therefore, this approach can be envisaged as a promising therapeutic strategy for loco-regional treatment of ovarian cancer.

• Authors: Isabella Monia Montagner, Anna Merlo, Debora Carpanese, Gaia Zuccolotto, Davide Renier, Monica Campisi, Gianfranco Pasut, Paola Zanovello, Antonio Rosato
• Journal: Oncoscience (Oncoscience) Vol. 2 Issue 4 Pg. 373-81 ( 2015) ISSN: 2331-4737 [Print] United States
• PMID: 26097871 (Publication Type: Journal Article)